anti-CD19 CAR T-cell therapy/IL-15 (Precigen/ZIOPHARM/Eden BioCell)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD19 CAR T-cell therapy/IL-15 (Precigen/ZIOPHARM/Eden BioCell)
Drug Alias NameCD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cellsRPM CD19-mbIL15-CAR-T cellsanti-CD19 CAR T-cell therapy mbIL15 and HER1t safety switch (NCI/MD Anderson Cancer Center)anti-CD19 CAR T-cell therapy co-expressing membrane-bound IL-15 (Precigen/ZIOPHARM)anti-CD19 CAR T-cell therapy/IL-15 (Precigen/ZIOPHARM) +[8] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-15 receptors agonistsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19Interleukin-15 receptors
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMacau +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer CenterAlaunos Therapeutics IncEden BioCell Ltd
Inactive CompaniesNational Cancer InstitutePrecigen Inc
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A